On March 28, 2023 Freenome, a privately held biotech company reported that Renown Health has joined as a partner for the Sanderson Study, Freenome’s study of its multiomics platform, in combination with real-world data to detect multiple cancers (Press release, Freenome, MAR 28, 2023, View Source [SID1234629469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study encompasses both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models. In addition, the Sanderson Study will build the necessary infrastructure to bridge the gap between clinical research and day-to-day clinical impact.

Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to detect cancer in its earliest stages using a standard blood draw.

"We are delighted to partner with Freenome to launch this far-reaching trial which has transformative potential," said Lee Schwartzberg, M.D., medical oncology section chief and the principal investigator for the Sanderson Study at Renown. "Studying the impact of merging real-world information from patients with multiomics technology holds the promise of a truly personalized approach to early detection of cancer."

Renown Health has multiple clinical trials currently available to patients in northern Nevada across a variety of specialties, including oncology, cardiology, neurology, pediatrics, and pulmonology.

Cancer is the second-leading cause of death in the Silver State, claiming the lives of more than 5,400 Nevadans each year. This number has increased since the last five-year plan estimate of 4,400 deaths per year.[1]

Promoting research to improve cancer prevention, detection, diagnosis and treatment is a key goal outlined in the Nevada Cancer Plan, 2021-2025, a framework developed by the Nevada Cancer Coalition in partnership with the Nevada Department of Health and Human Services.

Access and participation in clinical trials is a key component of the plan, which, Renown says, makes participation in the Sanderson Study even more significant.

"At the inception of the William N. Pennington Cancer Institute, we committed to not only provide the very best care possible to our community, but to also help improve outcomes through participation in research," said Max Coppes, M.D., PhD, MBA, cancer center director of the William N. Pennington Cancer Institute. "The research collaboration with Freenome has the potential to make a dream come true: Finding cancer early when it’s most treatable."

The Sanderson Study will enroll approximately 8,000 patients through Freenome’s clinical study partner network and numerous regional health systems across the United States.

"Renown is committed to making a difference in the health and well-being of patients in communities across the state of Nevada, and that includes access to innovative research," said Lance Baldo, M.D., chief medical officer at Freenome. "The combination of real-world data and multiomics is poised to transform the landscape of early cancer detection."

Freenome’s clinical studies are named for employees’ loved ones who fought cancer. This study honors Tim Sanderson, the loving father of a Freenome engineer.

For residents of Nevada interested in participating in the Sanderson Study, contact the William N. Pennington Cancer Institute clinical research coordinators at [email protected]. For more information on the Sanderson Study, visit the study webpage.